A portrait illuminates a metaphor for maldistribution of burden of disease, risk exposure, and long-standing inequity in health laid bare to the world during the COVID-19 pandemic.
AMA J Ethics. 2021;23(3):E283-284. doi:
10.1001/amajethics.2021.283.
This commentary explores legal, ethical, and practical considerations for pharmacists and prescribers working together to address uncertainty in drug prescribing.
AMA J Ethics. 2021;23(6):E471-479. doi:
10.1001/amajethics.2021.471.
Furthering clinicians’ understandings of how daily practice can respond to Black patients' experiences can help restore trust and mitigate racial and ethnic health inequity.
AMA J Ethics. 2021;23(6):E480-486. doi:
10.1001/amajethics.2021.480.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"